Stock Markets
America’s front line against fentanyl is a Golden Retriever named Goose
By Ted Hesson
SAN DIEGO (Reuters) – One of America’s most valuable defenders against fentanyl trafficking at the Mexico border uses his nose to root out illicit drugs, an old-school technique that authorities say is a key to reducing the flow of deadly synthetic opioids.
Goose, an enthusiastic Golden Retriever, weaves through a sea of idling cars on a warm afternoon at San Diego’s massive legal border crossing, one of the most transited in the world with roughly 100,000 people entering the U.S. each day.
The border crossing is open around the clock and dogs contend with exhaust fumes, hot pavement and unpredictable workdays that can go from routine to tense in seconds.
Now Goose and his handler, customs officer Joseph Arcia, trek inside to demonstrate to Reuters how the six-year-old canine can sniff out his training chew toy among the throngs of pedestrians crossing into the U.S. on foot, replicating what he and other dogs do to detect fentanyl and other contraband daily.
Goose sits when he finds the toy planted on a random volunteer crossing the border. Mission accomplished.
The Golden Retriever is one of 536 U.S. Customs and Border Protection canines trained to sniff out drugs, guns, ammunition, money and hidden passengers at America’s land border crossings, airports and seaports. The rise of illicit fentanyl and the epidemic of related overdoses prompted CBP to take the then-unprecedented step in 2017 of training drug-sniffing dogs to detect it, a program that has proved crucial to the agency’s efforts.
Despite millions of dollars in technology that allows CBP to scan vehicles and data analytics that help target possible smugglers, a dog’s sense of smell remains a vital tool for uncovering fentanyl and other narcotics.
Fentanyl is a powerful synthetic opioid that was approved by U.S. authorities for use as an anesthetic in 1968, but a spike in clandestine production and fatal overdoses in the past decade has made it a priority for law enforcement and health providers.
An estimated 75,000 people died from synthetic opioid overdoses in 2023, mostly involving fentanyl, according to the U.S. Centers for Disease Control and Prevention.
The vast majority of CBP fentanyl seizures occur at legal border crossings in Arizona and California, according to CBP statistics. Most convicted fentanyl traffickers in recent years have been U.S. citizens, U.S. Sentencing Commission figures show.
CBP Office of Field Operations canines have been involved with seizing more than 63,000 pounds [28,576 kg] of fentanyl since the program started, according to agency statistics.
President Joe Biden, a Democrat running for another term in Nov. 5 elections, has called on Republicans in Congress to increase funding for border security, including counter-fentanyl efforts at legal border crossings. CBP officials say the funding could help expand the use of canines, which includes a pilot program that has trained six dogs to smell for “precursor” chemicals used to make fentanyl.
Sidney Aki, the CBP field office director for the San Diego area, worked as a canine handler at the start of his career in the 1990s. Speaking to Reuters at the San Ysidro port of entry in late May, he said the dogs operated in conjunction with scanners and data analytics to root out fentanyl and other contraband.
“Of course, if we had more canines, if we had more personnel partnered up with canines, we would continue to do more and more,” he said.
STRONG MOTIVATION
At CBP’s canine academy in Front Royal, Virginia, customs officers from around the country are paired with their new four-legged partners, part of a four- to six-month process to teach the dogs to seek out contraband.
The drug-sniffing dogs are trained to detect six substances: marijuana, cocaine, heroin, methamphetamine, ecstasy and fentanyl, initially by filling chew toys with “pseudo-narcotics” that smell like the actual drug.
“That toy, that’s all they’re thinking about,” said Donna Sifford, the academy’s director, during an exclusive tour of the facility in mid-June. “When they smell those odors and sit, all they want to do is play with that toy.”
The academy – located on a picturesque 300-acre property in the Shenandoah River Valley – has training areas that simulate what will become the dogs’ real-world work environments, including an airport baggage screening room, mail room conveyor belt and an outdoor parking lot with dozens of dusty cars.
The dogs tend to be German Shepherds, Labradors, Dutch Shepherds and German Shorthaired Pointers, Sifford said. Goose is one of three Golden Retrievers in the program.
Most come from breeders in Europe, mainly Germany and the Czech Republic, while a smaller portion are American. They cost on average $11,000-$12,000 per dog and tend to retire when they reach age 8 or 9, she said.
While other hard drugs can have distinct scents – heroin sometimes smells like vinegar, for instance – fentanyl is usually odorless, at least to humans.
Dogs can learn to detect a new scent in three days on average, Sifford said, but before CBP could start training on fentanyl, the agency needed to develop safety protocols. Trainers always carry four doses of the opioid overdose drug Naloxone – which can also be administered to dogs – although they have not yet needed it, she said.
CBP has heard from authorities in other countries who want to learn about the fentanyl training techniques, including from recent outreach from Argentina and France, Sifford said. They have also had requests from U.S. states and localities.
Sifford acknowledges the work can be challenging for dogs at the border who have to deal with seasonally high temperatures, long work days and the stress of navigating traffic but said the work matches their breeding and temperament.
“When we’re selecting the dogs to go down to the southwest border, we’re looking for the higher-drive dogs that we know can actually work in that environment and maintain that pace,” she said.
‘ BEST (NYSE:) TECHNOLOGY’
Dogs have a sense of smell that is exponentially more powerful than humans with up to 200 times more olfactory receptors, according to a 2022 study published in the peer-reviewed Journal of Neuroscience.
Dogs can rapidly sweep through vehicle traffic, search suspicious cars and check lines of passengers. They are particularly useful for uncovering fentanyl, which can be moved in small quantities as pills or powder.
“They’re like biosensors,” said Michael Gould, a founding member of the New York City Police Department’s canine unit who now works as an expert witness in legal cases involving police dogs. “It’s really the best technology that’s available.”
The dogs do have limitations. They can typically only be out searching vehicles or people for about 20 minutes in warmer weather before they need a break, officials said. Drug-sniffing canines can also send false alarms, with studies showing a range of effectiveness.
And while CBP’s fentanyl seizures increased in recent years, the agency only appears to intercept a small percentage coming into the U.S.
A 2022 report on synthetic opioids issued by a group of U.S. lawmakers, government officials and outside experts estimated that only five metric tons of pure fentanyl would be enough to supply all U.S. opioid users for a year – a fraction of comparable heroin consumption by weight.
“That’s a whole year’s worth of fentanyl use in the United States that you can provide with three pickup truck loads,” said David Luckey, a senior researcher with the non-partisan, public policy-focused RAND Corporation, who worked on the report.
The street price of fentanyl has dipped to $1 per pill or lower in certain parts of the U.S., suggesting ample supply.
Pete Flores, CBP’s acting deputy commissioner, told Reuters his agency does not estimate how much fentanyl or other drugs might cross into the U.S. undetected but said the efforts aim to disrupt transit routes and business models used by criminal organizations.
“Every single shipment of narcotics, and particularly fentanyl, that we stop, we’re saving lives,” Flores said.
In a turbulent market environment, Five9 (NASDAQ:) Inc’s stock has touched a 52-week low, reaching a price level of $28.74. This significant downturn reflects a broader trend for the cloud software company, which has seen its shares plummet by -58.79% over the past year. Investors are closely monitoring Five9’s performance as it navigates through a period of heightened volatility and shifting industry dynamics, which have contributed to the stock’s current valuation at this low point. The company’s efforts to rebound from this position will be under scrutiny in the coming quarters as market participants look for signs of a strategic turnaround or further indications of market pressures.
In other recent news, Five9 Inc . has achieved an annual revenue run rate exceeding $1 billion in Q2, a significant milestone despite lowering its annual revenue guidance by 3.8% due to customer budget constraints. The company’s adjusted EBITDA margin rose to 17% of revenue, contributing to a strong operating cash flow of $126 million. The company also confirmed plans to reduce its global workforce by approximately 7% by the end of 2024, a strategic move projected to cost between $12 million and $15 million.
Five9’s recent acquisition of Acqueon, a firm specializing in proactive outbound omnichannel customer engagement, aims to expand its AI offerings and bolster its growth. This move is in line with the company’s focus on managing expenses and improving profitability, with initiatives like FedRAMP and expansion into India anticipated to improve gross margins.
In their analysis, Piper Sandler maintained an Overweight rating for Five9, with a steady price target of $47.00, while Needham and BTIG both maintained a Buy rating with price targets of $48.00 and $45.00 respectively. These ratings reflect the firms’ confidence in Five9’s strategic positioning and potential for growth, despite the current challenges and workforce reduction.
InvestingPro Insights
Amid the current market conditions, Five9 Inc’s recent performance can be put into perspective with select data from InvestingPro. The company’s market capitalization stands at roughly $2.15 billion, indicating the size and scale of the business amidst its challenges. Despite the stock’s decline, analysts are showing a hint of optimism, with 20 analysts having revised their earnings estimates upwards for the upcoming period. This could signal a potential turnaround in sentiment or underlying business performance.
Importantly, Five9’s liquid assets are reported to surpass short-term obligations, suggesting that the company maintains a degree of financial flexibility to navigate its current difficulties. Furthermore, while the stock is trading near its 52-week low, it’s worth noting that the relative strength index (RSI) suggests the stock is in oversold territory, which can sometimes precede a rebound in share price. Investors looking for comprehensive analysis and additional InvestingPro Tips on Five9 can find more insights, including 14 other tips, at https://www.investing.com/pro/FIVN.
In terms of financial health, the company operates with a moderate level of debt and is expected to become profitable this year, according to analysts’ predictions. These elements may offer some solace to investors considering the stock’s substantial price fall over the last year. For those seeking a deeper dive into Five9’s valuation and future prospects, the InvestingPro platform provides a fair value estimate of $45.04, which is considerably higher than the current trading price, suggesting potential undervaluation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TD Cowen reiterated its Buy rating on shares of Terns Pharmaceuticals (NASDAQ:TERN), following the company’s investor call. The call was held to manage expectations for the upcoming Phase 1/2 CARDINAL study data for chronic myeloid leukemia (CML). The firm noted the challenges in measuring the efficacy endpoint (EP) due to disease progression and the absence of treatment switch guidelines, which makes major molecular response (MMR) a challenging efficacy endpoint for Phase 1/2 trials.
The interim Phase 1/2 data aims to evaluate descriptive efficacy signals, considering patients’ baseline BCR-ABL levels and treatment history. The analyst highlighted that the once-daily (QD) dosing and the lack of food effect could potentially enhance the quality of life for patients compared to other allosteric tyrosine kinase inhibitors (TKIs).
Terns Pharmaceuticals has been focusing on the development of improved treatment options for CML. The company’s approach to dosing, which does not require food intake, may offer a more convenient alternative for patients, potentially leading to better adherence and outcomes.
The topline data from the 6-month Phase 1/2 CARDINAL study is anticipated to be available in 2025. This data will provide further insights into the treatment’s efficacy and safety, which are critical factors in the ongoing development and potential approval process.
Investors and stakeholders in Terns Pharmaceuticals are expected to closely monitor the progress of the CARDINAL study, as it could have a significant impact on the company’s future prospects and position in the CML treatment landscape.
In other recent news, Terns Pharmaceuticals has experienced significant developments. The biopharmaceutical company reported robust earnings and revenue results, with Mizuho Securities maintaining an Outperform rating on Terns shares, citing strong enthusiasm for the company’s drug, TERN-701, a potential treatment for chronic myeloid leukemia.
The firm expects the first interim Phase 1 CARDINAL study data for TERN-701 in December.
Terns also announced the appointment of Elona Kogan as its new chief legal officer, a move that underscores the company’s strategic development and pipeline advancement.
The company also secured an extension of its office lease in Foster City, California, through 2027, reflecting Terns Pharmaceuticals’ operational stability and long-term planning.
In terms of clinical trials, Terns has made progress in its ongoing Phase 1 study of TERN-701, with interim findings suggesting the drug can be administered once daily with or without food.
This development, coupled with the forthcoming Phase 1 data for another of Terns’ drugs, TERN-601—an oral GLP-1 receptor agonist for obesity—expected next month, underscores the company’s commitment to innovative therapies.
These recent developments, from financial performance to executive appointments and clinical trials, highlight Terns Pharmaceuticals’ ongoing efforts to advance its strategic objectives and deliver on its mission. The company’s activities are closely watched by investors and industry analysts, including those from Mizuho Securities, who continue to support the company’s potential.
InvestingPro Insights
As Terns Pharmaceuticals (NASDAQ:TERN) navigates the complexities of its Phase 1/2 CARDINAL study, investors are keeping a keen eye on the company’s financial health and stock performance. According to InvestingPro, Terns holds more cash than debt, which is a positive signal for financial stability. Additionally, with five analysts revising their earnings upwards for the upcoming period, there is a sense of optimism about the company’s potential performance.
However, it’s important to note that Terns is not currently profitable and has been quickly burning through cash, which may raise concerns about long-term sustainability. The company’s P/E Ratio stands at -5.71, reflecting these profitability challenges. Despite these hurdles, Terns has managed a 1 Year Price Total Return of 45.42%, indicating some investor confidence in the company’s growth prospects. The anticipated fair value from analysts stands at 15 USD, while the InvestingPro Fair Value is calculated at 5.8 USD, highlighting a divergence in valuation perspectives.
For those looking for more in-depth analysis, additional InvestingPro Tips on Terns Pharmaceuticals can be found at https://www.investing.com/pro/TERN, offering a comprehensive look at the company’s financial details and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PARIS (Reuters) – French President Emmanuel Macron discussed the importance of maintaining support for Ukraine and the need for a ceasefire in Gaza during talks on Friday with German Chancellor Olaf Scholz, said the French presidency.
Regarding Ukraine, the two leaders expressed their determination to support the country “for as long and as intensively as necessary” in its war against Russia, the Elysee said.
Forex2 years agoForex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Stock Markets2 years ago
Morgan Stanley: bear market rally to continue
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
